51 results about "Hepatic function" patented technology

Systems and methods are provided for monitoring a immunosuppressant drug level and renal function, hepatic function, or a combination thereof in a patient, comprising obtaining a small volume blood sample from the patient; determining the level of at least one immunosuppressant drug in the small volume blood sample and determining the level of a second immunosuppressant drug or analyzing the renal function, the hepatic function, or a combination thereof in the patient. In some embodiments, the immunosuppressant drug levels are determined using a liquid chromatography tandem mass spectrometry (LC-MS / MS) procedure. Also provided are kits for use in any of the systems and methods described herein.

A liver-mimetic device and method include a 3D polymer scaffold having a matrix of liver-like lobules with hepatic-functioning particles encapsulated within the lobules. In some embodiments, each liver-like lobule is hexagonal in structure and the matrix is in a honeycomb arrangement. In some embodiments, the hepatic-functioning particles are hepatic progenitor cells. In other embodiments, the hepatic-functioning particles are polymer nanoparticles adapted to capture pore-forming toxins.

The present invention discloses a heat-clearing and fire-lowering tea and the preparation method thereof, wherein the heat-clearing and fire-lowering tea comprises the following weight percentage compositions of components: 15 to 40 percent of lonicera, 10 to 30 percent of Florists Chrysanthemum, 2 to15 percent of Semen Cassiae, 15 to 40 percent of green tea, 0 t 20 percent of artichoke, and 0 to 20 percent of ilex kudincha. The present invention selects pure natural raw materials without any pesticide residue or any pollutant, without any additive such as sugar or antiseptic, and has the effects on the patient to clear the fire and refresh the consciousness, nourish the vitality and decrease the fat, eliminate the toxins and keep youthfulness, calm the hepatic function and brighten the eyes, fight against cancer and aging process, and improve the immunity, with good efficacy to release severe thirsty due to hotness and cure sore throat.

A simulation system for simulating functions of biological organs, comprising a biological model in which the functions of the biological organs are expressed by mathematical models. The biological model comprises a hepatic metabolism model block having specified input and output relating to hepatic function for simulating the hepatic function. The system further comprises arithmetic means for calculating an output value by using measurable status variables of a liver based on input value to the hepatic metabolism model block.

Systems and methods described herein determine an objective metric for analyzing health of a patient's liver. In some embodiments, the system may include a scanner that can detect radiation counts responsive to administration of radioactive compound to a patient. Further, the system may include an image detection module that can access image data responsive to the detected radiation counts by the scanner. The image detection module can programmatically identify a first region of interest corresponding to a liver of the patient from the image data. A parameter calculator module can programmatically determine a first attribute associated with the first region of interest and calculate a first parameter indicating health of the liver of the patient based at least in part on the first attribute associated with the first region of interest.

The invention belongs to the field of medicinal chemistry. Specifically, the invention relates to a prodrug containing a tiopronin structure showed by the following general formula I or a tautomer and a stereisomer of the prodrug, a stereisomer mixture or pharmaceutically acceptable solvate of the stereisomer mixture, a preparation method of the prodrug, a pharmaceutical composition, and application of the pharmaceutical composition serving as an anti-hepatitis c drug. This type of compounds or pharmaceutical compositions thereof can be used for curing hepatitis c, and also has the effects of protecting hepatic tissues and hepatic cells, and improving hepatic function.

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the STAT test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, or suspected of having, Chronic Hepatitis C, Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), or any chronic liver disease.

This invention provides a efficiently new induction model of hepatic oval cell. In this model significantly inducing the production of embryonic stem cell endogenous oval cell by using HGF and EGF, the whole induction method is fairly convenient, induction cycle is also very short. Utilizing very little embryonic stem cell provenance source can induce to generate sufficient hepatic oval cell which is contented to clinical requirement by using the invented induction model of hepatic oval cell, it also can be used for clinical category such as hepatic oval cell transplant, hepatic tissue engineering and so on, it can play a part in assistant supportive treatment or curing disease for Liver function failure, hepatic metabolic disease caused by various kinds of reason.

The invention discloses a gene Mindin and an application of an inhibitor thereof in a hepatic ischemia reperfusion injury, and belongs to the field of functions and applications of genes. After the experiment is carried out through a hepatic ischemia reperfusion injury model by taking a gene Mindin knockout rat and a Mindin transgenosis rat with a hepatic cell specificity as experimental subjects, the result shows that the hepatic necrosis of the gene Mindin knockout rat is obviously inhibited and the hepatic function of the gene Mindin knockout rat is obviously improved in comparison with a wild-type C57 rat, but the hepatic necrosis of the Mindin transgenosis rat with the hepatic cell specificity is obviously increased and the hepatic function of the hepatic necrosis Mindin transgenosis rat is seriously deteriorated. Thus, the gene Mindin has a function of deteriorating hepatic cells, especially, the gene Mindin has the function of deteriorating the hepatic ischemia reperfusion injury. Aiming at the function of the gene Mindin, the gene Mindin can serve as a medicine target for screening medicines for treating the hepatic ischemia reperfusion injury. The inhibitor of the gene Mindin can be used for preparing the medicines for treating the hepatic ischemia reperfusion injury.

Provided is a method of measuring blood coagulation time, the method being capable of LA detection easily and with high sensitivity as compared with the method recommended by the ISTH, without being affected by deficiency of blood coagulation factors even in a blood sample of a warfarin taker, a person who suffers from vitamin K deficiency, or a hepatic failure patient. Disclosed is a method of measuring the blood coagulation time to detect lupus anticoagulant, the method including adding a buffer solution composition containing blood coagulation factors to a blood sample before measurement or at the time of measurement of the blood coagulation time, and measuring the blood coagulation time.

The invention discloses a novel traditional Chinese medicine composition for treating cardiac carcinoma and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the raw materials of lignum dalbergiae odoriferae, szechuan lovage rhizome, alosewood, costus root, pericarpium citri reticulatae, poria, frankincense, myrrh, Chinese lobelia herb, whiteflower patrinia herb, ground beetle, malayan pangolin, leech, rhubarb, Chinese goldthread, honeysuckle flower, philippine violet herb, grassleaf sweelflag rhizome, radix sophorae tonkinensis, medicated leaven, immature bitter orange, India madder root, dried ginger, peppermint, sophora flavescens ait, and the like. The traditional Chinese medicine composition can be prepared into any common oral preparation by the conventional preparation method of traditional Chinese medicines. The invention can obviously improve symptoms, such as upper gastrointestinal hemorrhage, food retention or non-smooth feeling, stomach pain, marasmus, anemia, edema, hepatic failure, coma, gastroduodenal obstruction, and the like and has definite and significant clinical curative effect and quick effectiveness. Because the traditional Chinese medicine composition is combined by medicaments which are specified as both food and medicine in a national pharmacopoeia basically, the invention has the advantages of low cost, almost no toxic or side effect, and the like.

A Chinese medicine in the form of mixture, cream, or infusion for treating the liver function damage, such as pain in costal regions, vomiting, nausea, icterus, etc, is prepared from 3 Chinese-medicinal materials including notoginseng, root of common fibraurea, etc.

An orally applied disotat for treating hepatic dysfunction is prepared from disotat as active component and proper auxiliaries. It may be tablet, coated tablet, effervescent tablet, enteric tablet, chewing tabet, capsule, softgel, pill, etc.

According to the invention, a farnesoid X receptor (FXR) antagonist is applied to treatment of HBV infected persons. Serum bile acid in the HBV infected persons can promote HBV replication and expression through the FXR, and the FXR receptor antagonist can inhibit the HBV replication and expression, promote HBV cleaning, improve hepatic functions, inhibit hepatic fibrosis and hepatic cirrhosis and reduce risk of metastasis of liver cancer.

The invention discloses application of an MT (Metallothionein) gene serving as a target gene for preventing and treating the AFB1 (Aflatoxin B1) caused hepatic injury of a duck. The pollution of AFB1 in feed is wide; after an animal ingests the AFB1, the production performance of the animal is caused to decrease, even to die. The AFB1 is mainly enriched in a hepatic organ of the animal, damages a hepatic function, and even induces cancerization. Protein coded by the MT gene can further inhibit the AFB1 induced cancerization and apoptosis of a hepatic cell through enhancing the antioxidant ability of the hepatic cell and regulating and controlling the expressions of a cancer inhibiting factor and an apoptosis promotion related gene; the AFB1 induced injury of primary hepatocyte of the duck can be effectively inhibited. According to the invention, a novel target gene is provided for developing a medicine for preventing and treating the AFB1 caused hepatic injury of the duck and developing a novel feed additive.

The invention provides a composition for improving an in vivo metabolism parameter. A composition containing D-psicose as an active ingredient, which can be used for giving D-psicose at a dose of 5 g or more for each time continuously for the purpose of decreasing an in vivo metabolism parameter, i.e., a uric acid level and / or a level of a hepatic function indicator component. The level of 15 g gamma-GTP is significantly decreased from week 4 of the ingestion of the composition. When the composition is given continuously at a dose of 5 g or more in terms of D-psicose content three times a day, the level of gamma-GTP is significantly decreased from week 4 of the ingestion of the composition and the level of ALP is significantly decreased from week 2 of the ingestion of the composition.

The invention belongs to the field of pharmaceutical chemistry and particularly relates to a tiopronin structure containing prodrug represented by a general formula I shown in the description or tautomers, stereomers, stereomer mixtures or pharmaceutically-acceptable solvates thereof, preparation methods for the prodrug or the tautomers, stereomers, stereomer mixtures or pharmaceutically-acceptable solvates thereof, pharmaceutical compositions and use of the pharmaceutical compositions as hepatitis C resisting drugs. The compounds or pharmaceutical compositions thereof can be applied to the treatment of hepatitis C and meanwhile play roles in protecting hepatic tissue and hepatic cells and improving hepatic functions.

The invention belongs to the field of medicines, and provides a medicine for treating acute liver failure. The invention discovers that a compound kinsenoside (Kinsenoside(3-(R)-3-beta-D-Glucopyranosyloxybutanolide) can effectively prevent the development of acute liver failure, and in a mouse liver failure model, the compound has the activities of improving liver function and oxidative stress injury, and reducing inflammatory factor secretion and the like; and meanwhile, hepatic cell apoptosis is inhibited by protecting the structural integrity of mitochondria, so that the compound has remarkable liver protection activity and can be used as a medicine for treating the acute liver failure for treating the acute liver failure.

The invention provides a making method of coffee wine. According to the technical scheme of the making method of the coffee wine, in the process of brewing wine, coffee beans or coffee bean products of a certain amount are added in a fermentation stage or an aging stage after the fermentation is terminated, and the coffee wine is made according to the brewing technology of dry red wine. The making method of the coffee wine is simple to operate; however, through the making method of the coffee wine, the color of the wine can be stabilized by combination with the caffeic acids and the gallotannic acids of the coffee beans or the coffee bean products; the anti-oxidation function of the wine is promoted. In addition, the coffee wine has functions that the wine does not have, and has effects of promoting urination, removing dampness, easing constipation, improving hepatic functions when being drunk with an appropriate amount, appetizing and helping feeding, and allaying tiredness to a human body.

The invention belongs to the field of medicines, and relates to an application of D-chiro-inositol in preparation of a hepatic fibrosis resisting medicine. Systematic researches of the influence on blood serum liver function indexes AST and ALT activity of bile duct ligation (BDL) model group mice, the improvement on a liver pathological structure, the influence on the hepatic fibrosis degree and liver tissue hydroxyproline content, the influence on the blood serum and the liver tissue oxidative stress level, the influence on inflammatory reactions, and the like, prove that the D-chiro-inositol can inhibit the generation and improvement of hepatic fibrosis, and is expected to be developed into a potential active ingredient of a hepatic fibrosis resisting medicine.

Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.

The invention relates to the field of culture of primary cells in vitro, in particular to a culture medium and culture method for hepatocytes and application of the hepatocytes. The culture medium forthe hepatocytes comprises a proliferation culture medium comprising the following components: a liquid basic culture medium, galactose, insulin-transferrin-sodium selenite, proline, niacinamide, ornithine, a transforming growth factor alpha, an epidermal growth factor, dexamethasone, Y-27632, A-83-01 and CHIR99021. A long-term in-vitro amplification system for primary hepatocytes is established;and the hepatocytes are completely differentiated without cell dedifferentiation or transdifferentiation during passage amplification culture, the carcinogenic risk is reduced, and the difference between hepatic functions of hepatocytes matured by induction and primary hepatocytes is small.

Provided is a method of preparing a three-dimensional cell spheroid, the method including forming the cell spheroid by co-culturing adipose-derived stem cells or mesenchymal stem cells with hepatocytes. According to the cell spheroid prepared by the method, the secretome secreted by the adipose-derived stem cells affects hepatocyte maturation, and therefore, hepatic functions of the finally formed three-dimensional cell spheroid, i.e., organoid, may be enhanced. Further, a composition including a culture medium of the adipose-derived stem cells may prevent or treat liver diseases including hepatitis, hepatotoxicity, cholestasis, fatty liver, etc., and may enhance hepatic functions.

The invention discloses a rice-bran fatty alkanol and dioscorea opposita powder composition capable of reducing cholesterol and relates to the technical field of health-care foods. The composition isprepared from the following raw materials in percentage by mass: 60%-80% of rice-bran fatty alkanol and 20%-40% of dioscorea opposita powder. According to the rice-bran fatty alkanol and dioscorea opposita powder composition capable of reducing the cholesterol, disclosed by the invention, the accumulation of the cholesterol is controlled, the deposition of the cholesterol on the internal wall of ablood vessel can be prevented, part of deposits can be cleared away, and the composition can resist tumors and has the advantages of improving physical strength, enhancing endurance and vigor, improving response sensitivity and emergency capability, improving metabolism, strengthening myocardial functions, meanwhile, lowering serum cholesterol and triglyceride content and improving hepatic functions.

The invention discloses an in-vitro liver perfusion device which comprises a support, a clamping mechanism, a hepatic portal vein perfusion channel and a hepatic artery perfusion channel, wherein the clamping mechanism is arranged on the support and is used for clamping a ligament of the in-vitro liver so as to hang the in-vitro liver; the hepatic portal vein perfusion channel is slidably arranged on the support, and one end of the hepatic portal vein perfusion channel is communicated with a hepatic portal vein of the in-vitro liver; the hepatic artery perfusion channel is slidably arranged on the hepatic portal vein perfusion channel, and one end of the hepatic artery perfusion channel is communicated with the hepatic artery of the in-vitro liver. The ligament of the in-vitro liver is clamped through the clamping mechanism arranged on the support, so that the in-vitro liver is hung, the in-vitro liver is in a free sagging state, the whole in-vitro liver is not extruded, and the situation that the liver function is damaged due to stacking of the in-vitro liver when the in-vitro liver is directly contained in a container is prevented; and the hepatic portal vein perfusion channel and the hepatic artery perfusion channel are arranged, so that a perfusion tube can be conveniently inserted and is not easy to fall off, and perfusate can be prevented from leaking at the insertion part.

A simulation system for simulating functions of biological organs, comprising a biological model in which the functions of the biological organs are expressed by mathematical models. The biological model comprises a hepatic metabolism model block having specified input and output relating to hepatic function for simulating the hepatic function. The system further comprises arithmetic means for calculating an output value by using measurable status variables of a liver based on input value to the hepatic metabolism model block.

Provided is a novel use of ADAMTS13 in the medical field. Use of ADAMTS13 as a biomarker for monitoring the onset of hepatopathy, hepatic ischemia / reperfusion injury or hepatic function after liver transplantation; a method for examining hepatopathy, a method for examining hepatic ischemia / reperfusion injury or a method for examining hepatic function after liver transplantation, each method comprising measuring or monitoring ADAMTS13 activity in a sample obtained from a mammal; and a therapeutic agent for a disease selected from the group consisting of hepatopathy, hepatic ischemia / reperfusioninjury and hepatic dysfunction after liver transplantation, the agent comprising ADAMTS13 or a modification thereof.

The invention relates to compositions and methods using various combinations of at least one of phytosterols, lunasin peptide and plant extracts, optionally in combination with at least one of, soy extracts, beta-glycolipides and different adjuvants such as, castor oil, polyethylene glycol, or beta-cyclo dextrin, for controlling blood sugar levels, altered insulin resistance and / or hepatic function in a subject, treating an immune related disorder, treating liver damage and restoring liver function, treating, preventing, ameliorating, reducing or delaying the onset of acute or chronic toxic effect of a drug, and for enhancing the therapeutic effect of a therapeutic agent in a subject.